



# Corporate Presentation

NOVEMBER 2021

# Forward Looking Statements

This presentation (together with any other statements or information that we may make in connection herewith) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to Kiniksa Pharmaceuticals, Ltd. (and its consolidated subsidiaries, collectively, unless context otherwise requires, “Kiniksa,” “we,” “us” or “our”). In some cases, you can identify forward looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “goal,” “design,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “strategy,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these identifying words. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding our commercial and clinical strategy; potential value drivers; potential indications; potential market opportunities and competitive position; ongoing, planned and potential clinical trials and other studies; timing and potential impact of clinical data; regulatory and other submissions, applications and approvals; commercial strategy and commercial activities; expected run rate for our cash, cash equivalents and short-term investments; expected funding of our operating plan; and capital allocation.

These statements involve known and unknown risks, uncertainties, and other important factors that may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements, including, without limitation, potential delays or difficulties with our clinical trials; potential inability to demonstrate safety or efficacy or otherwise producing negative, inconclusive or uncompetitive results; potential for changes in final data from preliminary or interim data; potential inability to replicate in later clinical trials positive results from earlier trials and studies; our reliance on third parties for manufacturing and conducting clinical trials, research and other studies; our ability to source sufficient drug product, as needed, to meet our clinical and commercial requirements; our inability to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities; potential for applicable regulatory authorities to not accept our filings or to delay or deny approval of, or emergency use authorization for, any of our product candidates or to require additional data or trials to support any such approval or authorization; delays, difficulty or inability successfully execute on our commercial strategy for ARCALYST; potential changes in our strategy, clinical trial priority, operating plan and funding requirements; drug substance and/or drug product shortages; substantial new or existing competition; potential impact of the COVID-19 pandemic, and measures taken in response to the pandemic, on our business and operations as well as the business and operations of our manufacturers, CROs upon whom we rely to conduct our clinical trials, and other third parties with whom we conduct business or otherwise engage, including the FDA and other regulatory authorities; and our ability to attract and retain qualified personnel.

These and the important factors discussed in our filings with the U.S. Securities and Exchange Commission, including under the caption “Risk Factors” contained therein, could cause actual results to differ materially from those indicated by the forward-looking statements made in this presentation. These forward-looking statements reflect various assumptions of Kiniksa's management that may or may not prove to be correct. No forward-looking statement is a guarantee of future results, performance, or achievements, and one should avoid placing undue reliance on such statements. Except as otherwise indicated, this presentation speaks as of the date of this presentation. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

This presentation also contains estimates, projections, and/or other information regarding our industry, our business and the markets for certain of our product candidates, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, clinical trials, studies and similar data prepared by market research firms and other third parties, from industry, medical and general publications, and from government data and similar sources. Information that is based on estimates, forecasts, projections, market research, or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information.

ARCALYST is a registered trademark of Regeneron Pharmaceuticals, Inc. All other trademarks are the property of their respective owners.



# Developing Life-Changing Medicines For The Patients Who Need Them Most

## BY THE NUMBERS

- 1

FDA-approved therapy
- 40

Active and completed global clinical studies to date
- 3

Clinical-stage assets in multiple indications
- 200+

Employees and growing
- 3

Orphan Drug designations
- 2015

Company founded
- 2

Breakthrough designations
- 2021

Commercial availability of first and only FDA-approved therapy for recurrent pericarditis in the US: ARCALYST® (rilonacept)

## LOCATIONS



## MORE STRENGTHS



Passionate employees



A robust pipeline of product candidates for debilitating diseases



Find and deliver novel treatments for patients with a significant unmet need



Focus on immune modulation



Strong biologic rationale and validated mechanisms



In-house research team and lab



Kiniksa manufacturing for early-stage programs

## DISEASE AREAS

- Recurrent Pericarditis
- Cryopyrin-Associated Periodic Syndromes (CAPS)
- Deficiency of IL-1 Receptor Antagonist (DIRA)
- COVID-19-Related Acute Respiratory Distress Syndrome (ARDS)
- Giant Cell Arteritis (GCA)
- Prurigo Nodularis
- Rheumatoid Arthritis



# Portfolio of Four Immune-Modulating Assets

PROGRAM & TARGET	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	COMMERCIAL	COMMERCIAL RIGHTS
<b>ARCALYST®</b> (rilonacept) <sup>*1</sup> IL-1α & IL-1β	RECURRENT PERICARDITIS					<b>Worldwide</b> (Excluding MENA)
	CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS)					<b>Worldwide</b> (Excluding MENA)
	DEFICIENCY OF THE INTERLEUKIN-1 RECEPTOR ANTAGONIST (DIRA)					<b>Worldwide</b> (Excluding MENA)
<b>Mavrilimumab<sup>2</sup></b> GM-CSFRα	COVID-19-RELATED ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)					<b>Worldwide</b>
	GIANT CELL ARTERITIS					<b>Worldwide</b>
<b>Vixarelimab<sup>3</sup></b> OSMRβ	PRURIGO NODULARIS					<b>Worldwide</b>
<b>KPL-404</b> CD40	RHEUMATOID ARTHRITIS <sup>4</sup>					<b>Worldwide</b>



\* Approved in the U.S.

1) The FDA granted Breakthrough Therapy designation to ARCALYST for recurrent pericarditis in 2019 and Orphan Drug designation to ARCALYST for pericarditis in 2020. The European Commission granted Orphan Drug designation to ARCALYST for the treatment of idiopathic pericarditis in 2020; 2) The FDA granted Orphan Drug designation to mavrilimumab for giant cell arteritis in 2020; 3) The FDA granted Breakthrough Therapy designation to vixarelimab for the treatment of pruritus associated with prurigo nodularis in 2020; 4) Kiniksa plans to initiate a Phase 2 proof-of-concept trial in patients in the fourth quarter of 2021. The planned trial will provide safety and characterization of chronic administration as well as the potential to evaluate KPL-404 across a range of other autoimmune diseases ; IL-1α = interleukin-1α ; IL-1β = interleukin-1β; GM-CSFRα = granulocyte macrophage colony stimulating factor receptor alpha; OSMRβ = oncostatin M receptor beta; MENA = Middle East and North Africa



# ARCALYST®



## IL-1 $\alpha$ and IL-1 $\beta$ cytokine trap

Disease Area: Recurrent pericarditis<sup>1</sup>; painful and debilitating auto-inflammatory cardiovascular disease

Competition<sup>2</sup>: First and only FDA-approved therapy for recurrent pericarditis

Regulatory: U.S. Orphan Drug designation in pericarditis; U.S. Breakthrough Therapy designation in recurrent pericarditis; European Commission Orphan Drug designation in idiopathic pericarditis

Status: FDA-Approved

Economics: 50/50 profit split on the approved indications in the U.S.

Rights: Kiniksa has the worldwide rights (excluding MENA) to recurrent pericarditis, CAPS and DIRA




1) ARCALYST is also approved and marketed for Cryopyrin-Associated Periodic Syndromes (CAPS) and maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in the United States; 2) Drugs@FDA: Arcalyst Prescribing Information, Ilaris Prescribing Information, Kineret Prescribing Information; Kaiser et al. Rheumatol Int (2012) 32:295–299; Theodoropoulou et al. Pediatric Rheumatology 2015, 13(Suppl 1):P155; Fleischmann et al, 2017 ACR/ARHP Abstract 1196; Kosloski et al, J of Clin Pharm 2016, 56 (12) 1582-1590; Cohen et al. Arthritis Research & Therapy 2011, 13:R125; Cardiel et al. Arthritis Research & Therapy 2010, 12:R192; Hong et al. Lancet Oncol 2014, 15: 656-666; IL-1 $\alpha$  = interleukin-1 $\alpha$ ; IL-1 $\beta$  = interleukin-1 $\beta$ ; MENA = Middle East North Africa


# Recurrent Pericarditis U.S. Prevalence Estimated to be ~40K Patients

~14K patients with inadequate response to conventional therapy and persistent underlying disease

CLEAR CALL TO ACTION: ~14K PATIENTS




## Key Areas of Unmet Need in Patients with Recurrent Pericarditis



Klein A, Cremer P, Kontzias A, Furqan M, Tubman R, Roy M, Magestro M. Annals of Epidemiology. 2019;36:71; 2) Lin D, Majeski C, DerSarkissian M, Magestro M, Cavanaugh C, Laliberte F, Lejune D, Mahendran M, Duh M, Klein A, Cremer P, Kontzias A, Furqan M, Tubman R, Roy M, Mage. (Nov, 2019). Real-World Clinical Characteristics and Recurrence Burden of Patients Diagnosed with Recurrent Pericarditis in the United States. Poster session presented at the American Heart Association, Philadelphia, PA.; 3) ClearView Forecasting Analysis 2019 Q1

Source: Kiniksa Pharmaceuticals data on file 2019; 1) Prevention of future episodes while on treatment

# Pericarditis Epidemiology



*All figures annual period prevalence*

**Approximately 14,000 recurrent pericarditis patients suffer from persistent underlying disease, with multiple recurrences and inadequate response to conventional therapy<sup>1</sup>**

- **~ 160,000:** Epidemiological analysis using large national surveillance databases to calculate the pooled annualized prevalence of pericarditis (***Basis for Orphan Drug Designation approval***)<sup>2</sup>
- **~125,000:** Approximately 75-80% are considered idiopathic (thought to be post-viral) and post cardiac injury<sup>3-5</sup>
- **~40,000:** Up to 30% experience at least one recurrence; some recur over multiple years<sup>6,7</sup>
- **~14,000:** Nearly 50% annual turnover with ~7,000 patients coming into the pool each year<sup>8</sup>

# ARCALYST: First and Only FDA-Approved Therapy for Recurrent Pericarditis

## Third indication for ARCALYST underscores utility in IL-1 mediated diseases



**Arcalyst**<sup>®</sup>  
(rilonacept) For Injection

**2008**

**2020**

**2021**

**CAPS**  
FDA Approved

**DIRA**  
FDA Approved

**Recurrent Pericarditis**  
FDA Approved

KINIKSA  
**oneconnect**<sup>™</sup>  
support made simple.



CAPS = Cryopyrin-Associated Periodic Syndromes ; DIRA = Deficiency of IL-1 Receptor Antagonist

# ARCALYST Label

ARCALYST is a patient-administered once-weekly subcutaneous therapy

ADULTS (18 years and older)	ADOLESCENTS (12 to 17 years)
<b>Loading dose:</b> <b>320 mg</b> delivered as two 160 mg (2 mL) injections	<b>Loading dose:</b> <b>4.4 mg/kg</b> delivered up to a maximum of 320 mg, delivered as 1 or 2 injections (not to exceed 2 mL/injection)
<b>Weekly maintenance dose:</b> <b>160 mg</b> delivered once weekly as a 2 mL injection	<b>Weekly maintenance dose:</b> <b>2.2 mg/kg</b> delivered up to a maximum of 160 mg (2 mL) injection, once weekly

The first injection of ARCALYST should be performed under the supervision of a healthcare professional.



**ARCALYST is supplied in sterile, single-use, 20-mL glass vials**

- Each vial contains 220 mg ARCALYST, a sterile, white to off-white lyophilized powder
- Reconstitution with 2.3 mL of preservative-free Sterile Water for Injection is required prior to subcutaneous administration of the drug
- The reconstituted ARCALYST is a viscous, clear, colorless to pale yellow, free from particulates, 80-mg/mL preservative-free solution

# ARCALYST Use in Clinical Practice

## Average Duration of Recurrent Pericarditis is 2 Years<sup>1</sup>

- The presence of certain baseline characteristics may identify patients who may benefit from longer-term treatment
- The mean duration of disease in RHAPSODY in patients prior to enrollment was 2.4 years

## Median treatment duration in RHAPSODY was 9 months, with a range up to 14 months, at the close of the randomized period

- ARCALYST treatment was associated with a 96% reduction in risk for pericarditis recurrence
- Patients on ARCALYST experienced no/minimal pericarditis pain for 92% of trial days<sup>2</sup>
- 74/75 patients continued into LTE for longer-term therapy, demonstrating a desire to continue to a duration of up to 24 months

## Data support treatment duration tailored to duration of autoinflammation

- Registry data indicate patients treated for 6 months have worse outcomes compared to patients treated for 9 months<sup>3</sup>
- The only events in the ARCALYST arm in the randomized period of RHAPSODY took place in the setting of temporary drug interruptions of 1-3 doses
- Continued ARCALYST treatment resulted in continued treatment response.

## Recent data from RHAPSODY showed median duration of continuous ARCALYST therapy at the 1-year anniversary of the LTE portion of the trial of approximately 20 months



1) D. Lin, et al.; Recurrence Burden in Recurrent Pericarditis: A US-Based Retrospective Study of Administrative Healthcare Claims; Quality of Care and Outcomes Research (QCOR) 2020 Scientific Sessions; 2) Compared to 40% of trial days in patients treated with placebo; 3) M. Imazo, et al.; Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study. European Journal of Preventative Cardiology 2019; LTE = long-term extension



# Collaborative Field Force to Drive Awareness, Overcome Access Barriers and Help Ensure Positive Patient and Physician Experience



## CLINICAL SALES SPECIALISTS

- **Focus:** ~2500 HCPs across ~800 accounts
- **Responsibility:** Physician accounts, disease education, Arcalyst promotion, account and territory plans, speaker program planning

## STRATEGIC ACCOUNTS

- **Focus:** ~350 payers and 5 Specialty Pharmacies
- **Responsibility:** Payer/specialty pharmacy relationship, strategic account planning, support sales team

## MEDICAL SCIENCE LIAISONS

- **Focus:** Subject Matter Experts and HCPs
- **Responsibility:** Disease awareness, data dissemination, advocacy development, account and payer support, speaker management


## KINIKSA ONECONNECT™

- **Focus:** Patients and caregivers, HCPs seeking reimbursement support for their patients
- **Responsibility:** Optimize patient and customer experience with Arcalyst and Kiniksa, provide seamless initiation, reimbursement, and adherence support






HCP = health care provider

# Specialty Cardiology Salesforce Expected to Reach ~70% of U.S. Recurrent Pericarditis Patients



# Comprehensive Support for Patients Through Kiniksa OneConnect™

## DISEASE AWARENESS AND ARCALYST PROMOTION



## THE PATIENT ACCESS LEADS PROVIDE ONE-ON-ONE SUPPORT, INCLUDING:

- Insurance coverage determination
- Explanation of benefits verification
- Assistance with prior authorizations and appeals
- Injection training support and education with ARCALYST Nurse Educators
- Identification of possible sources of financial assistance
- Help with ARCALYST shipment and delivery


## PATIENT ADVOCACY SUPPORT



# ARCALYST: A Breakthrough Treatment

## Engaging and Educating on Recurrent Pericarditis through Digital Marketing

[Why ARCALYST](#)[Breakthrough Results](#)[Safety & Administration](#)[Treatment Initiation](#)



### Finally, a breakthrough treatment

for your patients with recurrent pericarditis<sup>1</sup>

ARCALYST is indicated for the treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years and older.

Please see Important Safety Information throughout, and full Prescribing Information.

ARCALYST is a registered trademark of Regeneron Pharmaceuticals, Inc. Kiniksa OneConnect is a trademark of Kiniksa Pharmaceuticals.  
© 2021 Kiniksa Pharmaceuticals (UK), Ltd. All Rights Reserved. 09/21 RIL-US-00126-21 (v3.0)

#### IMPORTANT SAFETY INFORMATION

**Warnings and Precautions**

- Interleukin-1 (IL-1) blockade may interfere with the immune response to infections. Treatment with another medication that works through inhibition of IL-1 or inhibition of tumor necrosis factor (TNF) is not recommended as this may increase the risk of serious infection. Serious, life-

**EXPAND +**

**Arcalyst**  
(rilonacept) For Injection

- Educational Webinars, Paid Search, Social Media and Advertising driving patient leads



~2,000 Patients & Caregivers  
Opted-In to Database



- Tailored communication plan developed to educate patients along disease journey and initiate appropriate patients on ARCALYST
- Individualized to each stage of the patient journey (Diagnosis, Initial recurrence, subsequent recurrence)

~75 patients from database are currently initiated on  
ARCALYST





# Pricing, Access and Distribution Considerations

## Pricing

- Kiniksa maintains the already established list price for ARCALYST **of \$20,000 per month**  
*Based on first and only FDA-approved therapy for recurrent pericarditis, in-line with specialty biologics with Breakthrough Therapy and Orphan Drug designation.*
- Helping to ensure patient affordability and access to treatment is one of our core principles and to this end, we offer a suite of programs to support affordability to eligible patients who are prescribed ARCALYST.

## Access

- Kiniksa's goal is to enable rapid and broad access to ARCALYST for patients with Recurrent Pericarditis, CAPS, and DIRA.
- Payer mix for ARCALYST is largely **commercial (60%) and Medicare (25%)**.
- Early payer engagement has increased awareness of recurrent pericarditis and the differentiated value of ARCALYST (145 meetings and 24 clinical presentations)\*
- **Kiniksa OneConnect™** is a personalized treatment support program for patients prescribed ARCALYST

## Distribution

- ARCALYST is distributed through a closed network of **5 specialty pharmacies and the Veterans Affairs**.
- The distribution network for ARCALYST was developed to provide a high and consistent level of patient support with broad access. Network pharmacies provide customized services to support patients.



\*Estimated through end of March  
CAPS = Cryopyrin-Associated Periodic Syndromes ; DIRA = Deficiency of IL-1 Receptor Antagonist


# Recurrent Pericarditis Demand Drove Overall ARCALYST Growth in Q3 2021

## Net Revenue

- \$12.1 million; 57% sequential growth

## Revenue Drivers

- Recurrent pericarditis was the major growth driver for Q3 sales, with recurrent pericarditis demand more than doubling and now representing over 3/4 of total ARCALYST sales
- Strong recurrent pericarditis demand is the primary growth driver with accelerated new patient initiations and strong retention rates
- CAPS and DIRA patient demand remained broadly consistent with previous quarter
- Revenue from inventory growth was marginal with the Q2 stocking being a one-off build at launch



**Kiniksa is expecting Q4 ARCALYST net revenue of \$16.0-17.0M**

Driven by anticipated robust growth in recurrent pericarditis demand





# Strong Execution Generated Patient Uptake, Physician Breadth and Early Payer Approvals in Recurrent Pericarditis

**Arcalyst**<sup>®</sup>  
(rilonacept) For Injection



*João*  
Living with  
Recurrent  
Pericarditis

## Early Broad Physician Adoption

- More than 200 physicians have prescribed ARCALYST for recurrent pericarditis since approval
- Engaged with more than 80% of initial target accounts with more than 80% of prescriber meetings conducted in-person


## Strong Early Payer Experience

- More than 90% of completed patient enrollment cases for recurrent pericarditis were approved for coverage
- Achieved broad access for recurrent pericarditis target population with greater than 190 million lives in the United States now with favorable coverage

## Compliance and Duration

- Two thirds of ARCALYST prescriptions for recurrent pericarditis have been written for 12 months of therapy
- Compliance to ARCALYST in recurrent pericarditis has been strong with refills happening on time
- An interval snapshot of data from the ongoing Phase 3 clinical trial, RHAPSODY, showed that the median duration of continuous ARCALYST therapy at the 1-year anniversary of the Long-Term Extension portion of the trial had reached approximately 20 months

# Summary of ARCALYST Profit Share Arrangement with Regeneron<sup>1</sup>



- Kiniksa is responsible for sales and distribution of ARCALYST in all approved indications in the United States.
- Kiniksa's license to ARCALYST includes worldwide rights, excluding the Middle East and North Africa, for all applications other than those in oncology and local administration to the eye or ear.
- Kiniksa covers 100% of development expenses related to approval of additional indications.
- We evenly split profits on sales with Regeneron, where profits are determined after deducting certain commercialization expenses, subject to specified limits, from ARCALYST sales.



1) Subject to description contained in definitive agreement; 2) Global net sales for CAPS, DIRA and recurrent pericarditis recognized as revenue on Kiniksa's income statement; 3) Including cost of product purchased from Regeneron as well as relevant Kiniksa overhead; CAPS = Cryopyrin-Associated Periodic Syndromes; DIRA = Deficiency of the Interleukin-1 Receptor Antagonist

# MAVRILIMUMAB

## Monoclonal antibody inhibitor targeting GM-CSFR $\alpha$

Disease Area: COVID-19-related acute respiratory distress syndrome (ARDS); Giant Cell Arteritis (GCA): chronic inflammatory disease of medium-to-large arteries

Competition<sup>1</sup>: Therapeutic options for patients hospitalized with COVID-19-related ARDS are limited; Only one FDA-approved therapy for GCA, but unmet needs remain

Regulatory: U.S. Orphan Drug designation in GCA

Status: Positive Phase 2 data in GCA reported in Q4 2020; Data from Phase 3 trial in severe COVID-19-related ARDS expected in Q1 2022

Economics: Clinical, regulatory and sales milestones; tiered royalty on annual net sales

Rights: Worldwide



1) Cortellis; UpToDate; Correspondence, Trial of Tocilizumab in Giant-Cell Arteritis, NEJM, 2017; GM-CSFR $\alpha$  = granulocyte macrophage colony stimulating factor receptor alpha

# Potential Broad Utility

## Mavrilimumab Data Across 3 Indications:

### COVID-19-related ARDS

Phase 2 trial in non-mechanically-ventilated patients with COVID-19 achieved its primary efficacy endpoint of the proportion of patients alive and free of mechanical ventilation at Day 29

### Giant Cell Arteritis

Phase 2 trial of mavrilimumab in giant cell arteritis achieved both the primary and secondary efficacy endpoints with statistical significance

### Rheumatoid Arthritis


Mavrilimumab was dosed in over 550 patients with rheumatoid arthritis through Phase 2b clinical studies in Europe and achieved prospectively-defined primary and secondary efficacy endpoints

*Mavrilimumab has been shown to be well-tolerated in giant cell arteritis, severe COVID-19-related ARDS, and rheumatoid arthritis clinical trials*

# Seamless Design Phase 2/3 Clinical Trial of Mavrilimumab in COVID-19-Related ARDS

**Key Inclusion Criteria:**

- Positive COVID-19 test within 14 days prior to randomization
- Hospitalized for COVID-19
- Bilateral pneumonia on chest x-ray or computed tomography
- Active fever or recently documented fever within 72 hours prior to randomization
- Clinical laboratory results indicative of hyper-inflammation
- Non-ventilated; requiring supplemental oxygen to maintain oxygen saturation (SpO2) ≥ 92% and not-intubated
- All patients should receive best standard of care, including steroids and antivirals, according to investigator judgement



Primary Efficacy Endpoint:

- Proportion of patients alive and without mechanical ventilation at Day 29.


Secondary Efficacy Endpoints:

- Mortality rate at Day 29
- Ventilation-free survival (time to ventilation or death) by Day 29
- Overall survival by Day 29

# Non-Mechanically Ventilated Patients Treated with Mavrilimumab Demonstrated a Reduction in Mechanical Ventilation and Death at Day 29 Pooled Across Dose Levels


## Phase 2 Data from the Phase 2/3 trial of Mavrilimumab in COVID-19-related ARDS

**Primary Endpoint: Proportion of Patients Alive and Free of Mechanical Ventilation at Day 29**



Mavrilimumab recipients experienced a 65% reduction in the risk of mechanical ventilation or death (Hazard Ratio (HR) = 0.35; p=0.0175).

**Key Secondary Endpoint: Mortality at Day 29**



Mavrilimumab recipients experienced a 61% reduction in the risk of death (HR= 0.39; p=0.0726).




# Mavrilimumab Reduced the Risk of Mechanical Ventilation or Death by 65% Versus Placebo at Day 29 Pooled Across Dose Levels

## Phase 2 data from the Phase 2/3 trial of Mavrilimumab in COVID-19-related ARDS

### Baseline Demographics & Characteristics:

- 43% non-whites, 57% males enrolled
- 96% received corticosteroids/dexamethasone
- 29% received antivirals/remdesivir
- Randomized number of patients by country
  - Brazil (37.72%)
  - United States (31.58%)
  - South Africa (27.19%)
  - Peru (2.63%)
  - Chile (0.88%)




KPL-301	75	75	75	75	74	73	71	69	68	67	65	65	65	64	64	63	63	59	59	59	59	59	55	52	50	49	47	47	45	38	18	3
Placebo	39	39	37	35	34	34	32	31	31	31	28	28	27	27	27	27	26	26	26	26	26	26	25	25	25	25	24	22	22	17	14	4

Note: Time to ventilation or death by Day 29 is defined as time (in days) from randomization to the date of death or start date of using mechanical ventilation (NIAID <= 2) by Day 29. All subjects who never had NIAID <= 2 by Day 29 will be censored at last assessment date of NIAID 8-point ordinal scale.

# Mavrilimumab Demonstrated Persistent Clinical Effect Through Day 90


## Phase 2 data from the Phase 2/3 trial of Mavrilimumab in COVID-19-related ARDS



KPL-301	75	75	70	69	68	67	67	67	67	66	66	66	66	65	65	65	63	55	43
Placebo	39	39	38	36	32	32	30	30	30	30	30	30	29	29	29	28	27	23	16


# Overview of Clinical Evaluation of Mavrilimumab in COVID-19

## Seamless clinical trial experience and on-going clinical development



- Data from a Phase 2 study in a diverse population of non-mechanically-ventilated patients with severe COVID-19 pneumonia suggest that mavrilimumab may be a potential **best-in-class** in reducing risk of death in patients with severe COVID-19-related ARDS
- In the context of other treatments being evaluated, Kiniksa is particularly encouraged by the benefit/risk of **GM-CSF receptor inhibition** with mavrilimumab given the **sustained treatment effect demonstrated throughout the 90-day observation period** after a **single administration**, and the well-tolerated safety profile to-date
- Kiniksa believes the way mavrilimumab blocks the body's counterproductive inflammatory reaction is **agnostic to coronavirus variant**


# Cross-Trial Comparison Demonstrates Mavrilimumab Phase 2 Data Well Positioned vs. Other Published Treatments in the Hospital Setting



**Sources:** Lancet 2021; 397: 1637–45; Lancet Rheum 2021; 3(10) : 690-697; Lancet Respir Med 2021; 9: 295–304; Lancet Respir Med 2021; Published 9/1 Online; NEJM 2021; 384;9; Front. Pharmac 2021; 12; Article 649472; Lancet Respir Med 2020; Published 6/16 Online; medRxiv. 2021 May 5;2021.05.01.21256470; NEJM 2020; 383;24; Nature Med 2021; 27(1752–1760); NEJM 2021; 384;16; NEJM 2021; 384;1; NEJM 2021; 385;5

# The Average Number of COVID-19 Hospitalizations Remains >6x the Influenza Average

## Future Waves of Hospitalization Expected Despite Vaccines



Vaccinations: <https://data.cdc.gov/Vaccinations/COVID-19-Vaccinations-in-the-United-States-County/8xkx-amqh>  
Daily Hosp [https://covid.cdc.gov/covid-data-tracker/#trends\\_dailycases\\_newhospitaladmissions|New\\_case|sum\\_previous\\_day\\_pediatric\\_and\\_adult\\_7DayAvg](https://covid.cdc.gov/covid-data-tracker/#trends_dailycases_newhospitaladmissions|New_case|sum_previous_day_pediatric_and_adult_7DayAvg)  
New Admissions <https://covid.cdc.gov/covid-data-tracker/#new-hospital-admissions>



# Phase 2 Clinical Trial of Mavrilimumab in GCA


## Key Inclusion Criteria:

- Age > 50 to 85 years
- Diagnosis of new-onset or relapsing/refractory GCA event within 6 wks prior to randomization (Biomarkers, Signs/Symptoms, imaging/biopsy)

**Screening:** Patients receive prednisone (or equivalent) at any dose required to induce remission at/before Randomization (resolution of symptoms and CRP < 20 mm in first hour)

## Design Advances vs. GiACTA:

- Clinical remission at randomization adds precision to time-to-event endpoint
- 26 wk vs 52 wks shortens trial duration
- Adjudicated events require biomarkers and Signs/Symptoms/Imaging
- Adequately powered for 20-40% relative/absolute delta vs PBO in time-to-event in pooled population (trends in disease subgroups)



## Treatment Period:

- Randomization 3:2 to mavrilimumab (150 mg) vs PBO SC q2wk)
- Prednisone (20-60 mg/day at Randomization) tapered over 26 weeks according to protocol-defined schedule

## Efficacy Endpoints:

- Primary: Time to adjudicated GCA flare by Week 26
- Secondary: Sustained remission rate at Week 26


## GCA Flare Definition (Adjudicated):

- Re-increase of CRP from normal to  $\geq 1$  mg/dL and/or of ESR from <20 mm to  $\geq 30$  mm
- and-
- At least one of the following signs/symptoms attributed by the Investigator to be new, worsening, or recurrent GCA:
  - Cranial symptoms (new-onset localized headache, scalp or temporal artery pain or tenderness, ischemia-related vision loss, or otherwise unexplained mouth or jaw pain upon mastication)
  - Extracranial symptoms (symptoms of polymyalgia rheumatica, claudication of the extremities)
  - Imaging (new or worsening angiographic abnormalities detected via MRI, CT/CTA, or PET-CT of the aorta or other great vessels or via ultrasound of the temporal arteries)



# Primary Efficacy Endpoint: Time-to-First Adjudicated GCA Flare by Week 26

## Mavrilimumab Phase 2 giant cell arteritis data



	Mavrilimumab (N=42)	Placebo (N=28)
Patients with Flare by Week 26, n (%)	8 (19)	13 (46.4)


Median time-to-flare by Week 26 could not be estimated in mavrilimumab recipients due to the low number of flares in the mavrilimumab treatment arm. The median time-to-flare for placebo recipients was 25.1 weeks. There was a 62% lower risk of flare in mavrilimumab recipients compared to placebo recipients.

# Unmet Need and Commercial Opportunity for Safe and Effective GCA Therapies

## Mavrilimumab Phase 2 giant cell arteritis data<sup>1</sup>


### New-Onset GCA

#### Patients With Flare by Week 26




\*Nominal p values

#### Sustained Remission at Week 26




### Relapsing/Refractory GCA

#### Patients With Flare by Week 26



\*Nominal p values

#### Sustained Remission at Week 26



### REMAINING UNMET NEED

- Cumulative U.S. GCA prevalence expected to grow 50% by 2035<sup>2</sup>
- ~50% of relapse/refractory patients are unable to achieve sustained remission within one year of starting treatment with approved biologics<sup>3</sup>
- Mechanistic (GM-CSFR $\alpha$  vs IL-6) and administrative (Q2WK vs QWK) differentiation
- Well-tolerated safety profile particularly important given large elderly patient population



1) Statistically significant primary (p=0.0263) and secondary endpoint (p=0.0038); consistent trend of efficacy in relapsing/refractory cohort; 2) Chandran AK, Udayakumar PD, Crowson CS, Warrington KJ, Matteson EL. The incidence of giant cell arteritis in Olmsted County, Minnesota, over a 60-year period 1950–2009. *Scand J Rheumatol*. 2015; 44(3):215–8.; Labarca C, Koster MJ, Crowson CS, et al. Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. *Rheumatology (Oxford)*. 2016;55(2):347–356.; Medcape; Trinity Lifesciences primary market research; Trinity Lifesciences analysis of Integrated 2016–2019 Medicare FFS & 2016–2019 IBM MarketScan Commercial & Medicare Supplemental data; 3) Trinity Partners Primary Market Research; Stone et al., *NEJM* 2017

# VIXARELIMAB

## Monoclonal antibody inhibitor targeting OSMR $\beta$

Disease Area: Prurigo Nodularis (PN); chronic inflammatory skin disease with pruritic nodules

Competition<sup>1</sup>: No FDA-approved therapies for PN

Regulatory: U.S. Breakthrough Therapy designation for the treatment of pruritus associated with prurigo nodularis

Status: Enrolling and dosing in a Phase 2b dose-ranging clinical trial; Data expected in 2H 2022

Economics: Clinical, regulatory and sales milestones; tiered royalty on annual net sales

Rights: Worldwide



1) Journal of the American Academy of Dermatology - Analysis of Real-World Treatment Patterns in Patients with Prurigo Nodularis: [https://www.jaad.org/article/S0190-9622\(19\)32744-6/pdf](https://www.jaad.org/article/S0190-9622(19)32744-6/pdf) ; OSMR $\beta$  = oncostatin M receptor beta


# Dual Mechanism Offers Potential Pruritus Relief and Nodule Improvement

## Vixarelimab Phase 2a prurigo nodularis data

Vixarelimab is the only mAb targeting OSMR $\beta$ , which mediates signaling of key cytokines (IL-31 & OSM)

### Primary Efficacy Endpoint

Mean change in weekly-average WI-NRS at Week 8 was -50.6% in vixarelimab recipients compared to -29.4% in placebo recipients (p=0.035).



### Secondary Efficacy Endpoint

30.4% of vixarelimab recipients achieved a PN-IGA score of 0/1 at Week 8 compared to 7.7% of placebo recipients (p=0.032).



*Representative Treatment Response*




mAb = monoclonal antibody; OSMR $\beta$  = oncostatin M receptor beta; IL-31 = interleukin-31; OSM = oncostatin M; WI-NRS = Worst-Itch Numeric Rating Scale; PN-IGA = prurigo nodularis-investigator's global assessment

# Vixarelimab Phase 2b Dose-Ranging Study in Prurigo Nodularis

## Data expected in 2H 2022

### Expected to enroll approximately 180 patients

- Moderate-to-severe prurigo nodularis experiencing severe pruritus.
- Patients are required to stop antihistamines and topical treatments, including corticosteroids, for at least two weeks prior to dosing.
- Prurigo nodularis treatments, other than study drug, are not allowed except for rescue.



### Primary Efficacy Endpoint (Week 16):

- WI-NRS (% change from baseline in weekly average)


### Key Secondary Efficacy Endpoints (Week 16):

- WI-NRS, weekly avg. (proportion of subjects achieving  $\geq 6$ -point reduction from baseline)
- WI-NRS, weekly avg. (proportion of subjects achieving  $\geq 4$ -point reduction from baseline)
- PN-IGA-Stage (proportion of subjects achieving 0 or 1 from baseline)

# Vixarelimab Dose-Ranging Phase 2b Study in Prurigo Nodularis

## Pharmacokinetic Simulation

*Supraphysiologic doses of IL-31 in a non-human primate IL-31 challenge model suggest a  $C_{eff}$  of 5-8ug/ml  
Data from studies of vixarelimab in prurigo nodularis and chronic pruritic diseases support a potential  $C_{eff}$  of approximately 5-8ug/ml*



# KPL-404

## Monoclonal antibody inhibitor interaction between CD40 and CD40L

Disease Area: Rheumatoid Arthritis; a chronic inflammatory disorder affecting many joints; External proof-of-concept previously established in broad range of autoimmune diseases: Sjogren's disease, systemic lupus, solid organ transplant and Graves' disease<sup>1</sup>

Scientific Rationale<sup>2,3</sup>: Attractive target for blocking T-cell dependent, B-cell-mediated autoimmunity

Status: Phase 1 single-ascending-dose study in healthy volunteers completed and supports further development in patients with optionality for testing SC and/or IV dosing; Expect to initiate Phase 2 proof-of concept trial in patients in Q4 2021

Economics: Clinical and regulatory milestones and royalty on annual net sales

Rights: Worldwide




1) Poster presentation at the Keystone Symposia: Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies: KPL-404, a CD40 antagonist, blocked antigen-specific antibody responses in an in vivo NHP model and demonstrated strong PK/PD correlation; 2) Elgueta, et al. Immunol Rev 2009, 229 (1), 152-172; 3) Peters, et al. Semin Immunol 2009, 21 (5) 293-300; CD40L = CD40 ligand; RO = receptor occupancy; TDAR = T-cell Dependent Antibody Response




# CD40/CD40L is an Essential Immune Pathway for T-Cell Priming and T-Cell Dependent B-Cell Responses

- CD40 is expressed on the surface of dendritic cells, B-cells, antigen-presenting cells and non-immune cell types
- Its ligand, CD40L (CD154), is expressed by activated T-cells, platelets, and other cell types



- CD40 ligation on DCs induces cell maturation by promoting antigen presentation and enhancing their costimulatory activity
- Mature DCs stimulate activated T-cells to increase IL-2 production that facilitates T-helper cells (Th) and cytolytic T-Lymphocyte (CTL) expansion
- CD40-stimulated DCs also secrete cytokines favoring Th1 cell differentiation and promoting Th cell migration to sites of inflammation
- CD40 ligation also provides a pro-inflammatory signal within the mononuclear phagocyte system

- Humoral immunity is dependent on a thriving B cell population and activation by Th cells; blockade of CD40/CD40L interaction has been shown to completely ablate primary and secondary TDAR response



- CD40 engagement triggers B-cell intercellular adhesion, sustained proliferation, expansion, differentiation, and antibody isotype switching leading to affinity maturation, which is essential for generation of memory B cells and long-lived plasma cells

- B-cells require contact-dependent stimulus from T cells through CD40/CD40L interaction independent of cytokines to trigger growth and differentiation




# KPL-404 Single-Ascending-Dose Phase 1 Study

First-in-human study to provide safety data and pharmacokinetics as well as receptor occupancy and TDAR

Part A (Single IV dose)

Part B (Single SC Dose)



- **Primary endpoints:** Safety and Tolerability
- **Secondary endpoints:** PK and ADA / CD40 RO in blood / Serum anti-KLH Ig levels
- **Exploratory endpoints:** Serum CXCL13 levels

**Notes:** Unless otherwise noted dose groups included 6 active/2 placebo subjects; \*1° KLH challenge for all SAD dose groups except 0.03 and 0.3 mg/kg, 2° KLH re-challenge only in 1, 3, and 10 mg/kg IV; \*\* Cohort included 2 active and 2 placebo subjects



SAD = single-ascending-dose; TDAR = T-cell dependent antibody response; KLH = keyhole limpet hemocyanin; RO = receptor occupancy; ADA = anti-drug antibodies

# Final Data from KPL-404 Single-Ascending-Dose Phase 1 Study

The randomized, double-blind, placebo-controlled first-in-human (FIH) study is designed to investigate the safety, tolerability, PK and PD properties of single-ascending intravenous (IV) and subcutaneous (SC) doses of KPL-404 in healthy subjects.

- 2 single-ascending-dose arms (SAD):
  - Single-dose KPL-404 0.03 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg or 10 mg/kg IV and
  - Single-dose KPL-404 1 mg/kg or 5 mg/kg SC

**Primary Endpoint:** Safety and tolerability of single ascending intravenous (IV) and subcutaneous (SC) doses of KPL-404 in healthy subjects.

- KLH challenge in 1 mg/kg, 3 mg/kg, and 10 mg/kg IV and 1 mg/kg and 5 mg/kg SC cohort

**Secondary Endpoints:** Pharmacokinetics and anti-drug antibody response following single IV and SC doses of KPL-404 in healthy subjects, serum anti- keyhole limpet hemocyanin (KLH) IgG levels

**Exploratory Endpoint:** Receptor occupancy of KPL-404 on CD40 in healthy subjects

## Preliminary Data:




- All dose escalations occurred as per protocol with no dose limiting safety findings. All 6 subjects dosed with KPL-404 3 mg/kg IV showed full receptor occupancy through Day 29, which corresponded with complete suppression of the T-cell Dependent Antibody Response (TDAR) to KLH through Day 29. Consistent dose relatedness was shown in the lower dose level cohorts, including 0.03 mg/kg, 0.3 mg/kg, 1 mg/kg IV and 1 mg/kg SC. Data collection for the higher dose level cohorts, 10 mg/kg IV and 5 mg/kg SC, is ongoing.
- The data to-date support subsequent study in patients, including potential IV or SC monthly administration.

## Final Data:

- KPL-404 showed dose-dependent increases in concentration across cohorts. All dose escalations occurred as per protocol with no dose-limiting safety findings.
- KPL-404 was well-tolerated, and there were no serious adverse events.
- Subjects dosed with KPL-404 10 mg/kg IV showed full RO through at least Day 71 and complete suppression of TDAR after KLH challenge and re-challenge through at least Day 57.
- Subjects dosed with KPL-404 5 mg/kg SC showed full RO through Day 43 and suppression of TDAR after KLH challenge through at least Day 29. These data confirm and extend previously-reported 3 mg/kg IV cohort data, in which RO and suppression of TDAR after KLH challenge were demonstrated through Day 29.
- The 3 mg/kg IV dose level had previously demonstrated complete suppression of memory TDAR response to a re-challenge on Day 29.
- Anti-drug antibodies to KPL-404 were suppressed for at least 57 days at 10 mg/kg IV; the suppression of antibody responses to the drug itself is an independent indicator of target engagement and pharmacodynamic effect


# RO and TDAR Suppression Shown Through Day 29 at 3mg/kg IV

## Preliminary KPL-404 Phase 1 data




# Final Data from KPL-404 Single-Ascending-Dose Phase 1 Study

## Pharmacokinetic profiles for KPL-404



# Final Data from KPL-404 Single-Ascending-Dose Phase 1 Study


## T-Cell Dependent Antibody Response (TDAR) for KLH antigen challenge




KLH = keyhole limpet hemocyanin

# Potential for Evaluation of KPL-404 in a Broad Range of Autoimmune Diseases

## Indications with Published Data<sup>1</sup>



## Indications with Pending Data & Trials Ongoing<sup>1</sup>



\*Indications evaluated with subcutaneous administration  
1) With the CD40 mechanism

## INDICATION SELECTION CRITERIA

- Robust Data or proof-of-concept supporting mechanism
- Differentiation vs. Competitors
- Commercial Attractiveness



Sources: 2019 numbers: <https://unos.org/data/transplant-trends/>; Hunter et al. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004-2014; Rheumatol Int. 2017 Sep;37(9):1551-1557; Overall Prevalence: Maciel et al. Arthritis Care Res (Hoboken) 2017; Qin et al. Ann Rheum Dis 2015; UpToDate; Baldini et al. Prevalence of Severe Extra-Glandular Manifestations in a Large Cohort of Patients with Primary Sjögren's Syndrome; 2012 ACR/ARHP Annual Meeting, ABSTRACT NUMBER: 2185; Wallin et al. The prevalence of MS in the United States A population-based estimate using health claims data, Neurology, March 5, 2019; Somers et al.; Prevalence of Systemic Lupus Erythematosus in the United States: Preliminary Estimates from a Meta-Analysis of the Centers for Disease Control and Prevention Lupus Registries; 2019 ACR/ARP Annual Meeting ABSTRACT NUMBER: 2886; Garg et al. JAMA Dermatol. 2017;153(8):760-764. doi:10.1001/jamadermatol.2017.0201 Sex- and Age-Adjusted Population Analysis of Prevalence Estimates for Hidradenitis Suppurativa in the United States; MayoClinic.org; Yale J Biol Med. 2013 Jun; 86(2): 255-260. N Engl J Med 2016;375:2570-81; <https://www.diabetesresearch.org/diabetes-statistics>; Nephcare.org; Kitiyakara C, Eggers P, Kopp JB. Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis. 2004 Nov;44(5):815-25; Rachakonda et al. J Am Acad Dermatol. 2014 Mar;70(3):512-6. doi: 10.1016/j.jaad.2013.11.013. Epub 2014 Jan 2. Psoriasis prevalence among adults in the United States; Yeung et al. Psoriasis severity and the prevalence of major medical co-morbidities: a population-based study; JAMA Dermatol. 2013 Oct 1; 149(10): 1173-1179; Hoover et al. Kidney Int. 2016 Sep; 90(3): 487-492. Insights into the Epidemiology and Management of Lupus Nephritis from the U.S. Rheumatologist's Perspective.

# Building Value at Kiniksa

## Corporate Priorities

---

### ARCALYST

Commercial launch in recurrent pericarditis (April 2021)  
Q2 net revenue \$7.7 million, Q3 net revenue \$12.1 million

---

### MAVRILIMUMAB

Phase 3 COVID-19-related ARDS data expected Q1 2022

---

### VIXARELIMAB

Phase 2b prurigo nodularis data expected in 2H 2022

---

### KPL-404

Expect to initiate Phase 2 proof-of-concept trial in rheumatoid arthritis in Q4 2021

---

**CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS EXPECTED TO FUND OUR CURRENT OPERATING PLAN INTO 2023**





# Financials

## Third Quarter 2021



## Q3 2021 Financial Results

Income Statement	Three Months Ended September 30,	
	2021	2020
Total Revenue	\$12.1M	N/A
Cost of Goods Sold	\$2.8M	N/A
Research and Development Expenses	\$19.2M	\$31.4M
Selling, General and Administrative Expenses	\$20.8M	\$11.8M
Total Operating Expenses	\$42.8M	\$43.2M
Net Loss	(\$30.5M)	(\$43.8M)

Balance Sheet	September 30, 2021	December 31, 2020
Cash, Cash Equivalents and Short-term Investments	\$200.2M	\$323.5M

**Q3 2021 Cash Reserves Expected to Fund Current Operating Plan into 2023**




# Appendix

# ARCALYST<sup>®</sup>

(rilonacept)


# Role of IL-1 $\alpha$ and IL-1 $\beta$ in the Autoinflammatory Cycle of Recurrent Pericarditis



Brucato A, et al. Int Emerg Med 2018 <https://doi.org/10.1007/s11739-018-1907-x>  
Dinarello CA, et al. Nat Rev Drug Discov 2012;11:633-652

# Addressable U.S. Opportunity of ARCALYST Estimated to be ~14K Patients

~7K new patients with multiple recurrences enter target pool annually



- ~7K new patients with repeat recurrences annually
- ~14K total patients with repeat recurrences annually at any point


Year	-4	-3	-2	-1	0
Incident case of acute pericarditis (1 <sup>st</sup> episode) <sup>1</sup>	117K	117K	117K	117K	117K
Incidence of initial RP patients (1 <sup>st</sup> recurrence) <sup>2</sup>	26K	26K	26K	26K	26K
Ongoing recurrent from year-1 <sup>3</sup>				7K	7K
Ongoing recurrent from year-2 <sup>3</sup>			7K	3.5K	3.5K
Ongoing recurrent from year-3 <sup>3</sup>		7K	3.5K	1.8K	1.8K
Ongoing recurrent from year-4 <sup>3</sup>	7K	3.5K	1.8K	0.9K	0.9K
Ongoing recurrent from year-5 <sup>3</sup>	3.5K	1.8K	0.9K	0.5K	0.5K
Ongoing recurrent from year-6 <sup>3</sup>	1.8K	0.9K	0.5K	0.2K	0.2K
Ongoing recurrent from year-7 <sup>3</sup>					0.1K

*Addressable Opportunity in U.S.*



1: Prevalence estimate from Imazio, et al. (2008); includes all etiologies (~80% idiopathic)  
 2: Mid point of 15-30% of initial recurrence rate published in ESC Guidelines given higher colchicine use today  
 3: Estimate for recurrence rate of subsequent recurrences from ESC Guidelines and Claims Analysis

# Pivotal Phase 3 Trial of ARCALYST in Recurrent Pericarditis



## Inclusion Criteria:

- All etiologies except infection and malignancy
- Present at screening with at least a third pericarditis episode, defined as at least 1 day with **NRS pain of ≥ 4** and **CRP value ≥ 1 mg/dL** within the 7-day period prior to first study drug administration
- Concomitant NSAIDs and/or colchicine and/or oral corticosteroid treatment in any combination

## Primary Efficacy Endpoint :

- Time-to-first-adjudicated pericarditis-recurrence in the RW period

## Major Secondary Efficacy Endpoints (16-weeks):

- Proportion of subjects who maintained Clinical Response
- Percentage of days with no or minimal pain
- Proportion of subjects with absent or minimal pericarditis symptoms


## CEC Adjudication Criteria:

- Typical pericarditis pain ( $\geq 1$  pain **NRS recording  $\geq 4$** ) AND elevated **CRP ( $\geq 1.0$  mg/dL)**, same day or  $\leq 7$  days
- Typical pericarditis pain ( $\geq 1$  pain **NRS recording  $\geq 4$** ) AND abnormal **CRP ( $>0.5$  mg/dL)**, same day or  $\leq 7$  days AND  $\geq 1$  **supportive evidence** of pericarditis
- Typical pericarditis pain (BUT pain **NRS recording  $\leq 4$** ) AND elevated **CRP ( $\geq 1.0$  mg/dL)**, AND  $\geq 1$  **supportive evidence** of pericarditis

# Baseline Demographics and Clinical Characteristics


## Pivotal Phase 3 Rilonacept Data

Baseline Demographics (n=86)




Total Number of Episodes Including Index and Qualifying Episodes	Run-in Period (n=86)
Mean	4.7


Prior Pericarditis History at Baseline (n=86)




SoC Received at Qualifying Episode (n=86)



Qualifying Episode CRP & NRS (n=86)




Pericarditis Manifestations at Qualifying Episode (n=86)



# Subject Disposition

## Pivotal Phase 3 Rilonacept Data

Median time to Monotherapy rilonacept = 7.9 weeks (7.0, 8.1)  
Median time to Pain Response<sup>2</sup> = 5.0 days (4.0, 6.0)  
Median time to CRP Normalization<sup>3</sup> = 7.0 days (5.0, 8.0)  
Median time to Treatment Response<sup>4</sup> = 5.0 days (4.0, 7.0)



1) Adverse Events n = 4 (4.7%); Protocol Deviation /Withdrawn Consent / Sponsor/Investigator Decision n = 3 (3.5%); CRP = C-reactive protein; NRS = Numerical Rating Scale 2; Pain response is NRS ≤ 2; 3) CRP normalization is CRP ≤ 0.5; 4) Treatment response is the combination of pain response and CRP normalization

# ARCALYST Initiation Resulted in Rapid Resolution of Pericarditis Episodes

## Pivotal Phase 3 RHAPSODY Data

***Rapid and sustained reductions in both reported pain and inflammation as early as after the first dose of ARCALYST***

*Median time to pain response = 5.0 days; Median time to CRP normalization = 7.0 days*

*Secondary endpoints that were assessed during the run-in period*

**5** days

Time to treatment response  
(median; 95% CI: 4, 7)\*

**97%**

Treatment response\* rate

**7.9** weeks

Time to ARCALYST monotherapy  
(median; 95% CI: 7, 8)



\*Time to treatment response was defined as the time from the first dose to the first day when pericardial pain was NRS  $\leq 2$  and CRP  $\leq 0.5$  mg/dL (measured within 7 days before or after the pain response). During the 12-week run-in period, 77 of 79 patients demonstrated a treatment response.

Klein AL, Imazio M, Cremer P, et al. Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis. *N Engl J Med*. 2021;384(1):31-41.  
ARCALYST (rilonacept) prescribing information 2021



# ARCALYST Demonstrated a Steroid-Sparing Treatment Effect

## Pivotal Phase 3 RHAPSODY Data

### ***Patients treated with ARCALYST discontinued corticosteroids***

---

***In the run-in period of the Phase 3 trial RHAPSODY, patients receiving corticosteroids at baseline were transitioned to ARCALYST monotherapy in 7.9 weeks***

**Each patient treated with corticosteroids at baseline achieved clinical response with ARCALYST monotherapy**

- 49% (27 of 86) of patients received corticosteroids at baseline
- None of the patients treated with corticosteroids at baseline and randomized to ARCALYST monotherapy experienced a recurrence while on therapy




# 96% Reduction in Risk of Pericarditis Recurrence

## Pivotal Phase 3 RHAPSODY Data

### ARCALYST reduced the risk of pericarditis recurrence

*The primary efficacy endpoint was time to first adjudicated pericarditis recurrence in the randomized withdrawal period.*



**96%**

**reduction in the risk of recurrent pericarditis**  
(hazard ratio: 0.04;  $p < 0.0001$ )

The median time to recurrence on ARCALYST could not be estimated due to the low number of recurrences

- 2 of 30 of patients treated with ARCALYST had a recurrence
- The 2 pericarditis recurrences with ARCALYST occurred during temporary interruptions of 1 to 3 doses of ARCALYST

The median time to recurrence on placebo was 8.6 weeks (95% CI: 4.0, 11.7)

- 74% (23 of 31) of patients treated with placebo experienced a recurrence at the time that the event-driven portion of the trial was closed
- Consistent with the expected washout pharmacokinetics of once-weekly ARCALYST at steady state

# 92% of Trial Days of No/Minimal Pain

## Pivotal Phase 3 RHAPSODY Data

***Patients on ARCALYST had significantly more trial days with no/minimal pain vs placebo***

*Secondary efficacy endpoint was assessed during the randomized withdrawal period*

# 92% of days

**Patients reported no/minimal (NRS≤2) pericarditis pain**

Compared with 40% of trial days in patients on placebo ( $p<0.0001$ ) at the secondary endpoint assessed at Week 16 of the randomized withdrawal period.

### **At Week 16 of the randomized withdrawal period:**

- A majority (81%) of patients maintained a clinical response measured at Week 16 of the randomized withdrawal period compared with 20% of patients on placebo ( $p=0.0002$ )



# Most Common ARCALYST Adverse Reactions:

## Injection-site reactions and upper respiratory tract infections

### Adverse experiences in RHAPSODY

EVENT	RUN-IN PERIOD	RANDOMIZED-WITHDRAWAL PERIOD				TOTAL (N=86)
	Rilonacept (N=86)	Rilonacept, Including Bailout (N=30)	Placebo, Including Bailout (N=31) <i>number of patients with event (percent)</i>	Rilonacept, Before Bailout (N=30)	Placebo, Before Bailout (N=31)	
Any adverse event	69 (80)	24 (80)	22 (71)	24 (80)	13 (42)	74 (86)
Adverse events according to maximum severity <sup>†</sup>						
Mild	52 (60)	16 (53)	17 (55)	16 (53)	9 (29)	47 (55)
Moderate	15 (17)	8 (27)	5 (16)	8 (27)	4 (13)	25 (29)
Severe	2 (2)	0	0	0	0	2 (2)
Serious adverse event	1 (1)	1 (3)	3 (10)	1 (3)	1 (3)	5 (6)
Adverse event leading to death	0	0	0	0	0	0
Adverse event leading to dose interruption	0	1 (3)	0	1 (3)	0	1 (1)
Adverse event leading to discontinuation of rilonacept or placebo	4 (5)	0	0	0	0	4 (5)
Cancer <sup>‡</sup>	0	1 (3)	0	1 (3)	0	1 (1)
Injection-site reaction	28 (33)	6 (20)	2 (6)	5 (17)	0	29 (34)
Infection or infestation	14 (16)	12 (40)	7 (23)	12 (40)	3 (10)	29 (34)
Upper respiratory tract infection	12 (14)	7 (23)	2 (6)	7 (23)	0	19 (22)

\*Patients with multiple events were counted once in each appropriate category

<sup>†</sup>Counted once, according to the maximum severity of the adverse event.

<sup>‡</sup>Cancer was an event of special interest.






# Appendix


# MAVRILIMUMAB

# Central Role of GM-CSF in Pathophysiology of Giant Cell Arteritis






# Preclinical Data Support the Mechanistic Rationale of Targeting GM-CSF in GCA

GM-CSF and its receptor, GM-CSFR $\alpha$ , shown to be elevated in GCA biopsies compared to control<sup>1</sup>



Mavrilimumab reduced arterial inflammation compared to control in an *in vivo* model of vasculitis<sup>2</sup>






# In Phase 2b Rheumatoid Arthritis Study Mavrilimumab Reduced CRP and IL-6, Key Markers of Disease Activity for Giant Cell Arteritis


Indicative of potential broad utility across spectrum of indications with similar biomarker profiles

C-reactive Protein (CRP)<sup>1</sup>



▲ Mavrilimumab 150 mg eow (n=79)      ▲ Mavrilimumab 30 mg eow (n=81)  
▲ Mavrilimumab 100 mg eow (n=85)      ▲ Placebo (n=81)

Interleukin-6 (IL-6)<sup>2</sup>



■ Placebo      ■ Mavrilimumab 30mg  
■ Mavrilimumab 100mg      ■ Mavrilimumab 150mg

# Phase 2 Data from the Phase 2/3 trial of Mavrilimumab in COVID-19-Related ARDS

The Phase 2/3 trial is a global, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of mavrilimumab treatment in adults hospitalized with severe COVID-19 pneumonia and hyperinflammation.

- In the non-mechanically ventilated cohort (Cohort 1), 116 patients with hypoxia and severe COVID-19 pneumonia/hyperinflammation were enrolled across sites in the United States, Brazil, Chile, Peru, and South Africa. Patients were randomized in a 1:1:1 ratio to receive a single intravenous (IV) dose of mavrilimumab 10 mg/kg, 6 mg/kg, or placebo.
- Baseline demographics were balanced across treatment arms: the population was ethnically/racially diverse (43% non-white), 49% were obese (body mass index  $\geq 30$ ), and 29% were older than 65 years.
- Local standard of care therapy: 96% received corticosteroids/dexamethasone and 29% received antivirals/remdesivir.

**Primary Efficacy Endpoint:** The proportion of patients alive and free of mechanical ventilation at Day 29.

**Key Secondary Efficacy Endpoints:** Time to two-point clinical improvement on the NIAID<sup>1</sup> scale, time to return to room air, and mortality at Day 29.

The prespecified evidentiary standard for Phase 2 endpoints was a 2-sided alpha value of 0.2, without adjustment for multiplicity.

**Non-mechanically ventilated patients (Cohort 1) treated with mavrilimumab demonstrated a reduction in mechanical ventilation and death at Day 29 pooled across dose levels:**

- The proportion of patients alive and free of mechanical ventilation at Day 29 was 12.3 percentage points higher in mavrilimumab recipients (86.7%) compared to placebo recipients (74.4%) (Primary efficacy endpoint;  $p=0.1224$ ).
  - Mavrilimumab recipients experienced a 65% reduction in the risk of mechanical ventilation or death (Hazard Ratio (HR) = 0.35;  $p=0.0175$ ).
- Day 29 mortality was 12.5 percentage points lower in mavrilimumab recipients (8%) compared to placebo recipients (20.5%) ( $p=0.0718$ ).
  - Mavrilimumab recipients experienced a 61% reduction in the risk of death (HR= 0.39;  $p=0.0726$ ).
- No apparent differences were observed between the 10 mg/kg and 6mg/kg IV treatment arms.

**Follow-up preliminary overall survival data from the cohort of non-mechanically ventilated patients at Day 60 and Day 90 demonstrated persistence of clinical effect of mavrilimumab in these patients and were consistent with the previously-reported Day 29 data.**

**Mavrilimumab was well-tolerated and exhibited a favorable safety profile:**

- One treatment-emergent serious adverse event related to study drug was reported on placebo, and there were no notable dose-related adverse events. Infections were noted in all groups including placebo recipients. All thrombotic events occurred in placebo recipients.



1) National Institute of Allergy and Infectious Diseases; ARDS = acute respiratory distress syndrome

# Baseline Demographics and Baseline Characteristics

## Phase 2 Portion of Phase 2/3 trial of Mavrilimumab in COVID-19-related ARDS



Median time to randomization from diagnosis was 7 days

### Baseline Demographics were Balanced Across Treatment Arms


Mean Age (years)	57.1
Age Range (years)	29-86
> 65 years old	29%
Non-white	43%
Body mass index $\geq$ 30	49%

### Local Standard of Care During 29-Day Treatment Period

Received Corticosteroids/Dexamethasone	96%
Received Antivirals/Remdesivir	29%



### Randomized Number of Patients by Country<sup>2</sup>



# Mavrilimumab was Well-Tolerated and Exhibited a Favorable Safety Profile


## Phase 2 Portion of Phase 2/3 trial of Mavrilimumab in COVID-19-Related ARDS

Category	KPL-301 10mg/kg (N=35) n (%)	KPL-301 6mg/kg (N=41) n (%)	Placebo (N=40) n (%)
Treatment Emergent Adverse Events (TEAEs)	19 (54.3)	19 (46.3)	26 (65.0)
TEAEs by Maximum Severity [1]			
Mild	10 (28.6)	8 (19.5)	6 (15.0)
Moderate	5 (14.3)	5 (12.2)	6 (15.0)
Severe	4 (11.4)	6 (14.6)	14 (35.0)
TEAEs related to KPL-301 or Placebo [2]	2 (5.7)	3 (7.3)	4 (10.0)
Serious TEAEs (SAE)	4 (11.4)	5 (12.2)	13 (32.5)
SAEs related to KPL-301 or Placebo [2]	0	0	1 (2.5)
TEAEs Leading to Death	3 (8.6)	4 (9.8)	9 (22.5)
TEAEs Leading to Dose Interruption	0	0	1 (2.5)
TEAEs of Special Interest	3 (8.6)	2 (4.9)	6 (15.0)



1) AESIs include: Hepatic Function Abnormality / induced Liver Injury, Acute and Delayed, Hypersensitivity Reactions, Neutropenia, Serious Infection, Worsening of Cytokine Release Syndrome


# Escalating Phases of Disease Progression with COVID-19



Source:  
Hasan K. Siddiqi MD, MSCR , Mandeep R. Mehra MD, MSc , COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal, Journal of Heart and Lung Transplantation (2020), doi: <https://doi.org/10.1016/j.healun.2020.03.012>

ARDS = Acute respiratory distress syndrome; CRP = C-reactive protein; IL = Interleukin; JAK = Janus Kinase; LDH=Lactate DeHydrogenase; SIRS = Systemic inflammatory response syndrome

# There are between 300k and 860k Cases of Adult ARDS in the U.S. Every Year; Significant Unmet Need Remains in These Populations



- Excludes ARDS associated with COVID-19
- Pediatric ARDS occurs less often
- Most common causes of ARDS are pneumonia (59%) and sepsis (16%)<sup>3</sup>
- 84.5% of ARDS cases require mechanical ventilation<sup>7</sup>
- Considerable mortality (~40%<sup>8</sup>) with no effective treatments outside mechanical ventilation

**~300,000 – 860,000 ARDS Cases Annually in US\***




1) KFF's State Health Facts. Population Distribution by Age [Kaiser Family Foundation estimates based on the Census Bureau's American Community Survey, 2008-2018].  
 2) Stefan MS, Shieh MS, Pekow PS, et al. J Hosp Med. 2013;8(2):76-82. doi:10.1002/jhm.2004  
 3) Bellani G, Laffey JG, Pham T, et al JAMA. 2016;315(8):788-800. doi:10.1001/jama.2016.0291  
 4) Mullins PM, Goyal M, Pines JM. Acad Emerg Med. 2013;20(5):479-486. doi:10.1111/acem.12134  
 5) ARDS Definition Task Force. JAMA 2012;307(23):2526-2533.  
 6) Laffey JG, Madotto F, Bellani G, et al. Lancet Resp Med. 2017;5(8):627-638  
 7) Bellani G, Laffey JG, Pham T, et al Am J Respir Crit Care Med 2017;195(1):67-77  
 8) Calfee CS, Delucchi KL, Sinha P, et al. Lancet Respir Med. 2018;6(9):691-698. doi:10.1016/S2213-2600(18)30177-2

\*There may be different ARDS phenotypes – some of which may not be ideal for GM-CSF inhibition. Further research is needed to understand which patient sub-types would best benefit from treatment with mavrilimumab



# Viral Infections Causing ARDS (i.e., influenza, H1N1, RSV, COVID-19, etc.) Have an Inflammatory Pathophysiology, Primarily Precipitated by Cytokine Storm

- Uncontrolled pro-inflammatory response, originating from the focal infected area, spreading through circulation and manifests as a **multiorgan failure** and **ARDS**
- Inflammation of the alveolar epithelial cells drives development of severe disease, destroying gas exchange and allowing **further viral exposure**
- Approach to treatment is **addressing host response** directly by targeting innate immune pathways that amplify inflammatory signals and contribute to epithelial damage



McGonagle, et al., Autoimmunity Reviews (2020), <https://doi.org/10.1016/j.autrev.2020.102537>

## Under-diagnosis of viral infections causing ARDS

- Viral infection is sufficient to cause severe pneumonia and ARDS, but it can also act in conjunction with or be followed by bacterial agents, (most commonly by *S. aureus* and *S. pneumoniae*)
- Clinicians fail to clinically diagnose influenza in **up to two-thirds** of patients with confirmed influenza



# GCA is a Serious Condition Characterized by Inflammation of Medium-to-Large Arteries

1

## Chronic inflammation of medium-to-large arteries

- GCA is characterized by inflammation of medium-to-large arteries with predisposition for the cranial branches of the carotid artery and is typically found in patients over 50 years old
- Due to the impact on the carotid arteries, GCA is often characterized by temporal-specific symptoms like headaches, jaw claudication, and scalp tenderness

2

## If left untreated, GCA can cause serious complications


- While the onset of symptoms tends to be subacute, patients can experience acute events, including permanent vision loss (~10-20% of patients) and/or aneurysms/dissections (~1-6% of patients)
- Due to the threat of these more serious complications, giant cell arteritis is considered a medical emergency

3

## GCA variants associated with unique presentations

- LV-GCA, characterized by the involvement of the aorta and its major proximal branches, is estimated to be involved in anywhere from ~30-80% of patients
- ~40-50% of GCA patients suffer from polymyalgia rheumatica, a rheumatic disease characterized by widespread aching and stiffness; symptoms are relieved immediately upon starting on low-dose steroids


# Current Treatment Paradigm for GCA Involves High-Dose Steroids Upon Clinical Suspicion



## TREATMENT APPROACH:

- All treated patients receive high-dose steroids, which are effective at preventing disease related complications; however, they may lead to life altering side-effects like osteoporosis and diabetes
- A few treaters initiate steroid sparing agents early in the treatment paradigm, relying on them more for the chronic treatment of GCA
- Others treat GCA in more of a stepwise fashion, adding new agents on top of steroids only following disease flares/relapse

# GCA U.S. Prevalence Estimated to be ~75-150k Patients



## Key Considerations to Market Sizing Approach

Wide Range	Under-Representation	Under-Representation
<p><b>High geographic variation</b></p> <p>GCA prevalence estimates vary across geographies with Northern European populations showing the highest rates and Asian populations the lowest</p> <p><b>Weighted by US demographics</b></p> <p>Given the demographic breakdown of the US, prevalence of GCA is likely ~75-150k (less than that of purely Northern Europeans, but more than estimates from Asian countries)</p>	<p><b>Represents Actively Managed Patients</b></p> <p>Medicare analysis does not capture GCA patients who were not actively managed within a given year; thus, the estimate from this analysis will exclude some remission patients or patients likely to relapse</p>	<p><b>Represents patients actively seen by a Rheum</b></p> <p>Rheumatologists reported the number of GCA patients they manage. Patients who are not actively managed would likely be excluded from these estimates</p>



Sources: 1.) Medicare analysis conducted 1/2018 2.) Trinity Partner's Quantitative Primary Market Research (n=74) 3.) Trinity Partner's Quantitative Primary Market Research (n=196) (includes data from screener portion of survey) 4.)Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004-2014, Hunter et al. 2017, 5.) Crowson et. al, 2017

# Mavrilimumab Phase 2 Study in Giant Cell Arteritis

## Primary and Secondary Endpoints Statistically Significant

**The randomized, double-blind, placebo-controlled, global Phase 2 trial consists of a 6-week screening period, a 26-week double-blind placebo-controlled treatment period, and a 12-week washout safety follow-up period.**

- Patients age 50 to 85 years with active GCA, confirmed by temporal artery biopsy and/or imaging, with erythrocyte sedimentation rate (ESR)  $\geq 30$  mm/hour or C-reactive protein (CRP)  $\geq 1$  mg/dL, and symptoms of GCA within 6 weeks from randomization, were included
- All patients were required to have achieved corticosteroid-induced remission (resolution of symptoms, ESR  $< 20$  mm/hour, CRP  $< 1$  mg/dL) prior to randomization.
- Seventy (70) patients were randomized 3:2 to mavrilimumab 150 mg or placebo biweekly injected subcutaneously, co-administered with a protocol-defined 26-week oral corticosteroid taper
- Patients were stratified by new onset (n=35) or relapsing/refractory (n=35) disease

**Primary Efficacy Endpoint:** Time-to-first adjudicated GCA flare by Week 26 in all treated patients

**Secondary Efficacy Endpoint:** Sustained remission at Week 26 in all treated patients


### Observations:

- The primary efficacy endpoint of time-to-first adjudicated GCA flare by Week 26 in all treated patients was statistically significant (Hazard Ratio = 0.38, p=0.0263)
  - Median time-to-flare by Week 26 could not be estimated in mavrilimumab recipients due to the low number of flares in the mavrilimumab treatment arm. The median time-to-flare for placebo recipients was 25.1 weeks
  - There was a 62% lower risk of flare in mavrilimumab recipients compared to placebo recipients
- The secondary efficacy endpoint of sustained remission at Week 26 in all treated patients was also statistically significant
  - The sustained remission rate at Week 26 was 33.3 percentage points higher in mavrilimumab recipients (83.2%) compared to placebo recipients (49.9%) (p=0.0038)
- While the study was not powered for disease cohorts, there was a consistent trend of efficacy across the new onset and relapsing/refractory cohorts
- **New Onset Cohort**
  - There was a 71% lower risk of flare in mavrilimumab recipients compared to placebo recipients (Hazard Ratio = 0.29, p=0.0873)
  - The sustained remission rate at Week 26 was 28.9 percentage points higher in mavrilimumab recipients (91.3%) compared to placebo recipients (62.3%) (p=0.0727)
- **Relapsing/Refractory Cohort**
  - There was a 57% lower risk of flare in mavrilimumab recipients compared to placebo recipients (Hazard Ratio = 0.43, p=0.1231)
  - The sustained remission rate at Week 26 was 30.6 percentage points higher in mavrilimumab recipients (72.2%) compared to placebo recipients (41.7%) (p=0.0668)
- Mavrilimumab was well-tolerated; there were no drug-related serious adverse events, and the rates of drug-related treatment-emergent adverse events between mavrilimumab recipients and placebo recipients were similar
- The 12-week washout safety follow-up period is ongoing, and additional analyses of this Phase 2 trial are planned. Next steps for the development program in GCA will be further informed by anticipated discussions with the U.S. Food and Drug Administration (FDA)


# Baseline Demographics and Clinical Characteristics

## Mavrilimumab Phase 2 Giant Cell Arteritis Data


Baseline Demographics (n=70)



Randomization Strata




Baseline Disease Characteristics (n=70)



## Secondary Efficacy Endpoint: Sustained Remission at Week 26

### Mavrilimumab Phase 2 Giant Cell Arteritis Data



*The sustained remission rate at Week 26 was 33.3 percentage points higher in mavrilimumab recipients (83.2%) compared to placebo recipients (49.9%) ( $p=0.0038$ ).*

# Time to Flare and Sustained Remission at Week 26

## Mavrilimumab Phase 2 Giant Cell Arteritis Data

Time to Flare by Week 26 and Sustained Remission at Week 26 - Total mITT Population		
	Mavrilimumab 150 mg (N=42)	Placebo (N=28)
Number of Subjects with Flare, n (%)	8 (19.0)	13 (46.4)
Primary Efficacy Endpoint: Time to Flare (weeks) by Week 26 [1]		
Median, 95% CI	NE (NE, NE)	25.1 (16.0, NE)
Hazard Ratio (Mavrilimumab vs Placebo), 95% CI [2]	0.38 (0.15, 0.92)	
P-value [3]	0.0263	
Secondary Efficacy Endpoint: Sustained Remission at Week 26 (%) , 95% CI [4]		
Difference in Proportions (95% CI) [5]	33.3 (10.7, 55.8)	49.9 (29.6, 67.3)
P-value [5]	0.0038	

Time to Flare by Week 26 and Sustained Remission at Week 26 by Randomization Strata				
	New-onset		Relapsing/Refractory	
	Mavrilimumab 150 mg (N=24)	Placebo (N=11)	Mavrilimumab 150 mg (N=18)	Placebo (N=17)
Number of Subjects with Flare, n (%)	3 (12.5)	4 (36.4)	5 (27.8)	9 (52.9)
Primary Endpoint: Time to Flare (weeks) by Week 26 [1]				
Median, 95% CI	NE (NE, NE)	NE (11.7, NE)	NE (16.4, NE)	22.6 (16.0, NE)
Hazard Ratio (Mavrilimumab vs Placebo), 95% CI [6]	0.29 (0.06, 1.31)		0.43 (0.14, 1.30)	
P-value [7] [8]	0.0873		0.1231	
Secondary Endpoint: Sustained Remission at Week 26 (%) , 95% CI [4]				
Difference in Proportions (95% CI) [5]	91.3 (69.3, 97.7)	62.3 (27.7, 84.0)	72.2 (45.6, 87.4)	41.7 (17.4, 64.5)
P-value [5][8]	28.9 (-2.7, 60.5) 0.0727		30.6 (-2.1, 63.2) 0.0668	

NE = Not estimable.

[1] Kaplan-Meier method used to estimate the survival functions for each treatment arm.

[2] Calculated based on a Cox proportional-hazards model with treatment as covariate and stratified by randomization strata.

[3] Comparison of KPL-301 and placebo with respect to time to flare calculated by using a log-rank test and stratified by randomization strata.

[4] Kaplan-Meier Survival Estimates with standard error and 95% CI for each arm.

[5] Two-sided p-value and 95% CI for the difference in sustained remission between two arms using normal approximation. Placebo arm is the reference.

[6] Calculated based on a Cox proportional-hazards model with treatment as covariate.

[7] Comparison of KPL-301 and placebo with respect to time to flare calculated by using a log-rank test.

[8] Subgroup analyses were not powered for significance; nominal p values reported.

# Time to Flare and Sustained Remission at Week 26

## Mavrilimumab Phase 2 Giant Cell Arteritis Data

Time to Flare by Week 26 and Sustained Remission at Week 26 - Total mITT Population		
	Mavrilimumab 150 mg (N=42)	Placebo (N=28)
Number of Subjects with Flare, n (%)	8 (19.0)	13 (46.4)
<b>Primary Efficacy Endpoint: Time to Flare (weeks) by Week 26 [1]</b>		
Median, 95% CI	NE (NE, NE)	25.1 (16.0, NE)
Hazard Ratio (Mavrilimumab vs Placebo), 95% CI [2]	0.38 (0.15, 0.92)	
P-value [3]	0.0263	
<b>Secondary Efficacy Endpoint: Sustained Remission at Week 26 (%) , 95% CI [4]</b>		
	83.2 (67.9, 91.6)	49.9 (29.6, 67.3)
Difference in Proportions (95% CI) [5]	33.3 (10.7, 55.8)	
P-value [5]	0.0038	

Time to Flare by Week 26 and Sustained Remission at Week 26 by Randomization Strata				
	New-onset		Relapsing/Refractory	
	Mavrilimumab 150 mg (N=24)	Placebo (N=11)	Mavrilimumab 150 mg (N=18)	Placebo (N=17)
Number of Subjects with Flare, n (%)	3 (12.5)	4 (36.4)	5 (27.8)	9 (52.9)
<b>Primary Endpoint: Time to Flare (weeks) by Week 26 [1]</b>				
Median, 95% CI	NE (NE, NE)	NE (11.7, NE)	NE (16.4, NE)	22.6 (16.0, NE)
Hazard Ratio (Mavrilimumab vs Placebo), 95% CI [6]	0.29 (0.06, 1.31)		0.43 (0.14, 1.30)	
P-value [7] [8]	0.0873		0.1231	
<b>Secondary Endpoint: Sustained Remission at Week 26 (%) , 95% CI [4]</b>				
	91.3 (69.3, 97.7)	62.3 (27.7, 84.0)	72.2 (45.6, 87.4)	41.7 (17.4, 64.5)
Difference in Proportions (95% CI) [5]	28.9 (-2.7, 60.5)		30.6 (-2.1, 63.2)	
P-value [5][8]	0.0727		0.0668	

NE = Not estimable.

[1] Kaplan-Meier method used to estimate the survival functions for each treatment arm.

[2] Calculated based on a Cox proportional-hazards model with treatment as covariate and stratified by randomization strata.

[3] Comparison of KPL-301 and placebo with respect to time to flare calculated by using a log-rank test and stratified by randomization strata.

[4] Kaplan-Meier Survival Estimates with standard error and 95% CI for each arm.

[5] Two-sided p-value and 95% CI for the difference in sustained remission between two arms using normal approximation. Placebo arm is the reference.

[6] Calculated based on a Cox proportional-hazards model with treatment as covariate.

[7] Comparison of KPL-301 and placebo with respect to time to flare calculated by using a log-rank test.

[8] Subgroup analyses were not powered for significance; nominal p values reported.







# Appendix

# VIXARELIMAB

# Vixarelimab Inhibits IL-31 & OSM Signaling Through OSMR $\beta$ but Avoids Inhibiting Signaling Critical to Hematopoiesis Through OSM/LIFR in vitro Studies



# Prurigo Nodularis U.S. Prevalence Estimated to be ~300K Patients



# Prurigo Nodularis is Typically Treated by Dermatologists Through a Combination of Medications and Behavioral Therapies; Treatment is Usually Unsuccessful

## Diagnosis of Prurigo Nodularis By Dermatologists

S

1 <sup>st</sup> Line	~100%	Emollients + Antipruritic Creams + Topical Corticosteroids + Antihistamines	
2 <sup>nd</sup> Line	~60-70%	Low-Dose Oral Corticosteroids, Intralesional Steroids, Occlusive Steroid Wrap	Vixarelimab may initially slot after steroids
3 <sup>rd</sup> Line	~25-30%	UV Phototherapy	
4 <sup>th</sup> Line	~20-30%	Other Systemic Therapy (e.g. MTX, Cyclosporine, Doxepin, Thalidomide)	

*Note: none of the above therapies are approved specifically for prurigo nodularis*


# Vixarelimab Phase 2a Study in Prurigo Nodularis

## Phase 2a Proof-of-Concept

**Objective:** Assess pruritus reduction

**Dose:** 720 mg SC loading dose --> 360 mg single SC QW thereafter

**Primary Efficacy Endpoint :** % change from baseline in weekly average Worst Itch-Numeric Rating Scale (WI-NRS)



### Inclusion Criteria

- Male or female aged 18 to 75 years, inclusive, at the time of consent
- Have a physician-documented diagnosis of prurigo nodularis that is confirmed by review of medical photography during the Screening Period. Duration of prurigo nodularis (since the time of first PN nodule) must be at least 6 months from the time of first PN nodule to Day 1, as affirmed by the subject
- Have at least 10 nodules of approximately 0.5 to 2 cm at the Screening Visit and Day 1. The nodules must be pruritic and present on at least 2 different anatomical locations (not be localized), involve the extremities, with extensor extremity involvement greater than the flexor extremity involvement. Nodules on the head (face and scalp) are not counted as an anatomical location for eligibility criteria. There must be normal appearing skin present in between nodules with the exception of atopic dermatitis. Each arm, each leg, and trunk are considered different anatomical locations
- Subject has moderate to severe pruritus, defined as WI-NRS  $\geq 7$  at the Screening Visit and a mean weekly WI-NRS  $\geq 5$  for each of the 2 consecutive weeks immediately prior to randomization
- Patients were required to stop antihistamines and topical treatments, including corticosteroids, for at least two weeks prior to dosing
- Prurigo nodularis treatments, other than study drug, were not allowed except for rescue

# Vixarelimab Phase 2a Study in Prurigo Nodularis

## Statistically significant primary efficacy endpoint of reduction in weekly-average WI-NRS at Week 8

Enrolled and treated 49 patients with moderate-to-severe prurigo nodularis (mean PN- IGA of 3.4) experiencing moderate-to-severe pruritus (mean WI-NRS score of 8.3)

- Randomized 1:1 to receive a loading dose of vixarelimab 720 mg (n=23) or placebo (n=26) subcutaneous (SC) followed by vixarelimab 360 mg or placebo SC weekly
- Data includes 49 subjects through the 8-week treatment period

**Primary Efficacy Endpoint:** percent change versus baseline in weekly-average WI-NRS at Week 8 (using the last observation carried forward analysis)


### Topline Observations:

- Least squares-mean change from baseline in weekly-average WI-NRS at Week 8 was -50.6% in vixarelimab recipients compared to -29.4% in placebo recipients (mean difference 21.1%; p=0.035)
- Median change from baseline in weekly-average WI-NRS at Week 8 was -69.8% in vixarelimab recipients compared to -36.1% in placebo recipients
- 30.4% of vixarelimab recipients achieved a PN-IGA score of 0/1 at Week 8 compared to 7.7% of placebo recipients (p=0.032)
- 52.2% of vixarelimab recipients demonstrated a  $\geq 4$ -point reduction in weekly-average WI-NRS at Week 8 compared to 30.8% of placebo recipients (p=0.109)
- In this Phase 2a trial, vixarelimab was well-tolerated by all subjects and no dose-limiting adverse experiences were observed. There were no serious adverse events or atopic dermatitis flares


# Vixarelimab Phase 2a Study in Prurigo Nodularis: Baseline Characteristics

General Characteristics*	Vixarelimab (n=23)	Placebo (n=26)	Total (n=49)
Age (Mean Years)	52	64	58
Sex (Male/Female)	10/13	10/16	20/29
Race			
White (n)	65.2% (15)	80.8% (21)	73.5% (36)
Black or African American (n)	21.7% (5)	11.5% (3)	16.3% (8)
Asian (n)	8.7% (2)	0	4.1% (2)
American Indian or Alaska Native (n)	0	3.8% (1)	2.0% (1)
Multiple (n)	4.3% (1)	0	2.0% (1)
Other (n)	0	3.8% (1)	2.0% (1)

Clinical Findings at Baseline: History of Atopy




Clinical Findings at Baseline: WI-NRS & PN-IGA



■ Vixarelimab  
■ Placebo


# Vixarelimab Phase 2a Data in Prurigo Nodularis

LS-Mean % Change in Weekly Average WI-NRS




Statistically Significant Primary Efficacy Endpoint of Reduction in Weekly-Average WI-NRS at Week 8

% of Vixarelimab Subjects with a Clinically Meaningful Response in WI-NRS



Majority of Vixarelimab Recipients Showed a Clinically Meaningful ≥4-Point Weekly-Average WI-NRS Reduction at Week 8

PN-IGA Score of 0 or 1



Significantly More Vixarelimab Recipients Attained A Clear/Almost Clear Lesion Score by Week 8





Vixarelimab = KPL-716  
WI-NRS = Worst-Itch Numeric Rating Scale  
LS = least squares



# Vixarelimab Phase 2a Study in Prurigo Nodularis: Statistically Significant Primary Efficacy Endpoint of Reduction in Weekly-Average WI-NRS at Week 8


Median change from baseline in weekly-average WI-NRS at Week 8 was -69.8%




Vixarelimab = KPL-716  
WI-NRS = Worst-Itch Numeric Rating Scale  
LS = least squares

# Vixarelimab Phase 2a Study in Prurigo Nodularis: Majority of Vixarelimab Recipients Showed a Clinically Meaningful $\geq 4$ -Point Weekly-Average WI-NRS Reduction at Week 8


% of KPL-716 Subjects with a Clinically Meaningful Response in WI-NRS




% of Placebo Subjects with a Clinically Meaningful Response in WI-NRS



KPL-716 Per Subject Plots




Placebo Per Subject Plots




# Vixarelimab Phase 2a Study in Prurigo Nodularis: Significantly More Vixarelimab Recipients Attained A Clear/Almost Clear Lesion Score by Week 8

PN-IGA Score of 0 or 1




$\geq 1$  Point Change in PN-IGA




# Vixarelimab Phase 2a Study in Prurigo Nodularis: Concordant Activity of Vixarelimab on PN-IGA and Pruritus

% of IGA 0-1 Subjects with  $\geq 4$  Point Change in WI-NRS



*85.7% of the subjects who achieved 0-1 on the PN-IGA scale were also 4-point responders on WI-NRS vs. none for placebo*

% of Subjects with  $\geq 4$  Point Change in WI-NRS and an IGA of 0-1



*50% of the subjects who had a clinically meaningful reduction in itch by week 8 also had an PN-IGA score of 0-1 vs. none for placebo*



Vixarelimab = KPL-716  
WI-NRS = Worst-Itch Numeric Rating Scale  
LS = least squares

# Vixarelimab was Well-Tolerated in Prurigo Nodularis Phase 2a Study

Summary of Adverse Events	Vixarelimab (n=23)	Placebo (n=26)
Any AE (n)	82.6% (19)	65.4% (17)
TEAE (n)	82.6% (19)	65.4% (17)
Drug-Related TEAE (n)	39.1% (9)	30.8% (8)
Serious TEAE	0	0
Drug-Related Serious TEAE	0	0
TEAE Leading to Treatment Discontinuation	0	0
Drug-Related TEAE Leading to Treatment Discontinuation	0	0
Serious TEAE Leading to Treatment Discontinuation	0	0
Drug-Related Serious TEAE Leading to Treatment Discontinuation	0	0
TEAE Leading to Death	0	0



AE = adverse event  
TEAE = treatment emergent adverse event

## Vixarelimab was Well-Tolerated in Prurigo Nodularis Phase 2a Study


System Organ Class Preferred Term	Vixarelimab (n=23)	Placebo (n=26)
Infections and Infestations (n)	30.4% (7)	46.2% (12)
Upper Respiratory Tract Infection (n)	17.4% (4)	3.8% (1)
Nasopharyngitis (n)	4.3% (1)	7.7% (2)
Gastroenteritis Viral (n)	4.3% (1)	0
Influenza (n)	4.3% (1)	0
Postoperative Wound Infection (n)	4.3% (1)	0
Subcutaneous Abscess (n)	4.3% (1)	0
Urinary Tract Infection (n)	0	11.5% (3)
Bronchitis (n)	0	3.8% (1)
Cellulitis (n)	0	3.8% (1)
Eczema Impetiginous (n)	0	3.8% (1)
Herpes Simplex (n)	0	3.8% (1)
Otitis Media (n)	0	3.8% (1)
Skin Infection (n)	0	3.8% (1)
Tooth Abscess (n)	0	3.8% (1)




# Appendix KPL-404

# KPL-404 Showed Encouraging Results in a Non-Human Primate Model of TDAR


**Mean KPL-404 PK  
(Intravenous Dosing)**



**Mean KPL-404 Receptor Occupancy (RO)**



**Mean KLH IgG**



*Showed linear pharmacokinetic profile with low variability between non-human primate subjects (n=7)*

*KPL-404 achieved 100% receptor occupancy for 2 weeks in all animals at 5mg/kg and 4 weeks in all animals at 10mg/kg*

*Complete suppression of primary T-cell dependent antigen response correlated with 100% receptor occupancy*





# Corporate Presentation

NOVEMBER 2021